LAMP3 and cancer: In a pan-cancer analysis, researchers further found that cDC1-derived LAMP3+ DCs and cDC2-derived LAMP3+ DCs are under different ligand-receptor control, suggesting potentially diverse functions (Cheng et al., 2021).